A model for lupus brain disease

Immunological Reviews

Volumn 248, Issue 1, 2012, Pages 56-67

  Diamond, Betty ^a   Volpe, Bruce T ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antibodies; Autoimmunity; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; D DWEYS PEPTIDE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEPTIDE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANTIBODY TITER; ARTICLE; BRAIN DAMAGE; CELL ACTIVATION; CELL SURVIVAL; EXPERIMENTAL MODEL; HIPPOCAMPUS; HUMAN; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INDUCTION;

AMYGDALA; ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN; BRAIN DISEASES; HIPPOCAMPUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; NEURONS; PEPTIDES; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84862738937     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01137.x     Document Type: Article

References (121)

1. Andrews BS, et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-1215.
2. Dixon FJ, Andrews BS, Eisenberg RA, McConahey PJ, Theofilopoulos AN, Wilson CB. Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum 1978;21:S64-S67.
3. Howie JB, Helyer BJ. The immunology and pathology of NZB mice. Adv Immunol 1968;9:215-266.
4. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotech 2011;2011:271694.
5. Talal N, Steinberg AD. The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol 1974;64:79-103.
6. Diamond B, Scharff MD. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci USA 1984;81:5841-5844.
7. Manheimer-Lory AJ, Davidson A, Watkins D, Hannigan NR, Diamond BA. Generation and analysis of clonal IgM- and IgG-producing human B cell lines expressing an anti-DNA-associated idiotype. J Clin Invest 1991;87:1519-1525.
8. Mietzner B, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008;105:9727-9732.
9. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992;22:1719-1728.
10. Zhang J, Jacobi AM, Wang T, Diamond B. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. Mol Med 2008;14:675-681.
11. Behar SM, et al. Impact of somatic mutation on the S107(T15) heavy-chain V region of antibodies reactive with self and nonself. Cold Spring Harb Symp Quant Biol 1989;54:921-931.
12. Behar SM, Corbet S, Diamond B, Scharff MD. The molecular origin of anti-DNA antibodies. Int Rev Immunol 1989;5:23-42.
13. Chien N, et al. Effect of somatic mutation on antibody affinity and specificity. Mt Sinai J Med 1986;53:181-186.
14. Diamond B, Chien N, Scharff M. Somatic mutation alters affinity and specificity. Ann Inst Pasteur Immunol 1985;136C:267-271.
15. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2011;50:1424-1430.
16. Wakasugi D, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 2012;39:79-85.
17. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002;11:856-864.
18. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genetics 2000;25:177-181.
19. van der Vlag J, Berden JH. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol 2011;31:376-389.
20. Katz JB, Limpanasithikul W, Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med 1994;180:925-932.
21. Hanrotel-Saliou C, Segalen I, Le Meur Y, Youinou P, Renaudineau Y. Glomerular antibodies in lupus nephritis. Clin Rev Allergy Immunol 2011;40:151-158.
22. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000;57:385-400.
23. Chowdhry IA, Kowal C, Hardin J, Zhou Z, Diamond B. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum 2005;52:2403-2410.
24. Kowal C, Weinstein A, Diamond B. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur J Immunol 1999;29:1901-1911.
25. Ray SK, Putterman C, Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci USA 1996;93:2019-2024.
26. Sharma A, Isenberg DA, Diamond B. Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 2001;16:479-484.
27. Briassouli P, Rifkin D, Clancy RM, Buyon JP. Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-beta and potentiates fibrosis. J Immunol 2011;187:5392-5401.
28. Defendenti C, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011;10:150-154.
29. Provost TT, Razzaque A, Maddison PJ, Reichlin M. Antibodies to cytoplasmic antigens in lupus erythematosus. Serologic marker for systemic disease. Arthritis Rheum 1977;20:1457-1463.
30. Shefner R, Kleiner G, Turken A, Papazian L, Diamond B. A novel class of anti-DNA antibodies identified in BALB/c mice. J Exp Med 1991;173:287-296.
31. Gaynor B, Putterman C, Valadon P, Spatz L, Scharff MD, Diamond B. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci USA 1997;94:1955-1960.
32. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001;44:432-441.
33. Monneaux F, Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev 2004;3:16-24.
34. Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-2082.
35. Hanly JG, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726-1732.
36. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010;28:61-73.
37. Kowal C, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006;103:19854-19859.
38. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-1193.
39. Alahlafi A, Wordsworth P, Wojnarowska F. Activation/inactivation of the classical pathway of complement in non-lesional skin of patients with systemic lupus erythematosus. J Cutan Pathol 2005;32:537-540.
40. Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012;8:183-189.
41. Munoz LE, et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010;10:38-42.
42. Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol 2006;28:131-143.
43. Roman MJ, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-3419.
44. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012;8:214-223.
45. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972;51:575-582.
46. Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002;39:121-127.
47. Harris EN, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-1214.
48. Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984;56:193-199.
49. Merrill JT. Endothelial cell damage and atherosclerosis. In: Lahita RG ed. Systemic Lupus Erythematosus. 5th edn. Amsterdam, The Netherlands: Elsevier, 2011:967-983.
50. Asherson RA, Cervera R, Merrill JT, Erkan D. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thrombosis Hemostasis 2008;34:256-266.
51. Pierangeli SS, Chen PP, Gonzalez EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006;13:366-375.
52. Roldan JF, Brey RL. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2007;9:109-115.
53. Mackay M, Ulug AM, Volpe BT. Neuropsychiatric systemic lupus erythematosus: mechanism of injury. Lahita RG ed. Systemic Lupus Erythematosus. 5th edn. Amsterdam, The Netherlands: Elsevier, 2011:491-511.
54. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75.
55. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine 1968;47:337-369.
56. Joseph FG, Scolding NJ. Neurolupus. Practical Neurol 2010;10:4-15.
57. Scolding NJ. Central nervous system vasculitis. Semin Immunopathol 2009;31:527-536.
58. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002;28:173-189.
59. Ghiran IC, Zeidel ML, Shevkoplyas SS, Burns JM, Tsokos GC, Kyttaris VC. Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production. Arthritis Rheum 2011;63:503-512.
60. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009;66:735-741.
61. Willison HJ. Biomarkers in experimental models of antibody-mediated neuropathies. J Peripher Nerv Syst 2011;16(Suppl):60-62.
62. Hanly JG, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:529-535.
63. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005;64:297-303.
64. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-1808.
65. Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002;78:599-606.
66. Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci 2011;65:549-560.
67. Gladman DD, Hussain F, Ibanez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002;11:234-239.
68. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispin JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 2011;31:769-779.
69. Cerami A. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. J Int Med 2011;269:8-15.
70. Dinarello CA. Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. J Int Med 2011;269:16-28.
71. Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor subtypes at central synapses. Science STKE 2004;2004:re16.
72. LeDoux JE. Emotion circuits in the brain. Annu Rev Neuorsci 2000;23:155-184.
73. Abramov AY, Duchen MR. Mechanisms underlying the loss of mitochondrial membrane potential in glutamate excitotoxicity. Biochim Biophys Acta 2008;1777:953-964.
74. Faust TW, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 2010;107:18569-18574.
75. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553-1558.
76. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006;54:2515-2522.
77. Lapteva L, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006;54:2505-2514.
78. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005;12:392-398.
79. Steup-Beekman G, Steens S, van Buchem M, Huizinga T. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007;16:329-334.
80. Diamond B, Volpe BT. Antibodies and brain disease: a convergence of immunology and physiology. PLoS Med 2006;3:e498.
81. Fragoso-Loyo H, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 2008;3:e3347.
82. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008;58:1130-1135.
83. Gono T, et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatol 2011;50:1578-1585.
84. Husebye ES, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1210-1213.
85. Yoshio T, Okamoto H, Minota S. Antibodies to bovine serum albumin do not affect the results of enzyme-linked immunosorbent assays for IgG anti-NR2 glutamate receptor antibodies: reply to the letter by Hirohata et al. Arthritis Rheum 2007;56:2813-2814.
86. Yoshio T, Onda K, Nara H, Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006;54:675-678.
87. Wang C, Khalil M, Ravetch J, Diamond B. The naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus. J Immunol 2003;170:4826-4832.
88. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25.
89. Johansson BB. Implications of the Blood-Brain Barrier and Its manipulation. Neuwelt EA ed. Implications of the blood brain barrier and its manipulation. NY: Plenum, 1989:389-410.
90. Kuang F, et al. Extravasation of blood-borne immunoglobulin G through blood-brain barrier during adrenaline-induced transient hypertension in the rat. Int J Neurosci 2004;114:575-591.
91. Tuor UI, McKenzie E, Tomanek B. Functional magnetic resonance imaging of tonic pain and vasopressor effects in rats. Magn Reson Imaging 2002;20:707-712.
92. Kowal C, et al. Cognition and immunity; antibody impairs memory. Immunity 2004;21:179-188.
93. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci USA 2006;103:678-683.
94. Mackay M, et al. Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with Systemic Lupus Erythematosus stratified by disease duration. Mol Med 2011;17:1349-1356.
95. Sternberg S. High-speed scanning in human memory. Science 1966;153:652-654.
96. Yetkin FZ, Rosenberg RN, Weiner MF, Purdy PD, Cullum CM. FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol 2006;16:193-206.
97. Etkin A, et al. Individual differences in trait anxiety predict the response of the basolateral amygdala to unconsciously processed fearful faces. Neuron 2004;44:1043-1055.
98. Emmer BJ, van der Grond J, Steup-Beekman GM, Huizinga TW, van Buchem MA. Selective involvement of the amygdala in systemic lupus erythematosus. PLoS Med 2006;3:e499.
99. Fragoso-Loyo H, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007;56:1242-1250.
100. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H, Subcommittee NR. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 2009;28:1319-1323.
101. Katsumata Y, et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 2007;34:2010-2017.
102. Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 2010;233:126-145.
103. Lahita RG. Systemic lupus erythematosus: learning disability in the male offspring of female patients and relationship to laterality. Psychoneuroendocrinology 1988;13:385-396.
104. Neri F, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004;13:805-811.
105. Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Ped Adolesc Med 2003;157:397-402.
106. Tincani A, et al. Impact of in utero environment on the offspring of lupus patients. Lupus 2006;15:801-807.
107. Lee JY, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 2009;15:91-96.
108. Contet C, Rawlins JN, Deacon RM. A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav Brain Res 2001;124:33-46.
109. Crawley JN. What's Wrong With my Mouse: Behavioral Phenotyping of Transgenic and Knockout Mice. 2nd edn. Hoboken, NJ: Wiley Interscience, 2007.
110. Deacon RM, Croucher A, Rawlins JN. Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res 2002;132:203-213.
111. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968;13:222-257.
112. Barker GR, et al. The different effects on recognition memory of perirhinal kainate and NMDA glutamate receptor antagonism: implications for underlying plasticity mechanisms. J Neurosci 2006;26:3561-3566.
113. Goodrich-Hunsaker NJ, Hunsaker MR, Kesner RP. Dissociating the role of the parietal cortex and dorsal hippocampus for spatial information processing. Behav Neurosci 2005;119:1307-1315.
114. Quirk GJ, Garcia R, Gonzalez-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 2006;60:337-343.
115. Bloom O, et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci USA 2011;108:10255-10259.
116. Petri M, Naqibuddin M, Sampedro M, Omdal R, Carson KA. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum 2011;41:194-202.
117. Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT. Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med 2011;269:36-44.
118. Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. Curr Opin Rheumatol 2007;19:421-426.
119. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009;9:449-456.
120. Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol 2006;179:173-179.
121. Rossi CC, Van de Water J, Rogers SJ, Amaral DG. Detection of plasma autoantibodies to brain tissue in young children with and without autism spectrum disorders. Brain Behav Immun 2011;25:1123-1135.